Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the retinoic acid derivative Ro 10-9359 cleared psoriasis lesions in over half of the patients, but most experienced side effects, including skin issues and altered liver enzyme levels.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.

Deuruxolitinib is generally safe for treating alopecia areata.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

This review suggests that PRP is an effective and safe technique for skin rejuvenation in aesthetic procedures, based on existing literature.

This paper argues that for lupus management, selective immunotherapies like anifrolumab and belimumab, which specifically target parts of the immune system, offer more effective treatment options compared to older, broad immunosuppressive strategies.

This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.

Tofacitinib might be used to treat hair loss.

Platelet-rich fibrin speeds up burn wound healing in rabbits.

This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.

Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.

This study reports the first successful use of zanubrutinib to treat a 15-year-old Chinese girl with severe refractory Evans' syndrome, resulting in a sustained recovery of platelet counts and haemoglobin levels.

This correspondence reports the case of a young woman with severe lipid storage myopathy due to a rare mutation, who showed significant temporary improvement with plasmapheresis and immunoglobulin treatment before stabilizing with riboflavin and coenzyme Q10 supplementation, challenging the initial assumption of an immune-mediated condition.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

In this study, a patient with recalcitrant lichen planopilaris and frontal fibrosing alopecia showed significant improvement after receiving four doses of the interleukin-23 monoclonal antibody tildrakizumab.

This study found that oral tofacitinib improved disease activity in patients with lichen planopilaris, suggesting it may be a promising treatment option for this condition.

This article reviews the use of platelet rich plasma in regenerative medicine and highlights the need for standardization in its preparation and application, reporting no new clinical results.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This study describes the development of a monoclonal antibody, 005-C04, which blocks PRLR-mediated signaling, suggesting its potential for furthering understanding of PRLR's role in health and disease.

This review highlights that deucravacitinib, a selective TYK2 inhibitor, shows promise as an effective treatment for psoriasis and other inflammatory skin diseases, though real-world evidence beyond psoriasis is still emerging.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This article in the International Journal of Dermatology reports on a case series where the drug upadacitinib was used to treat patients with recalcitrant lichen planopilaris, but no abstract or detailed results are provided to assess its efficacy or safety fully.

This study found that paxillin knockdown in human granulosa-derived cells and mouse models decreased androgen receptor protein levels and altered gene expression, suggesting paxillin's role in protecting against androgen excess effects, as observed in a polycystic ovary syndrome mouse model.

This review highlights encouraging findings on platelet-rich plasma's effectiveness in improving skin texture, firmness, and elasticity in aesthetic procedures but emphasizes the need for more standardized protocols and robust clinical trials.

This article reviews the potential of PRP as a treatment for spinal pain but calls for established use guidelines and protocols before wider clinical adoption, with no new clinical results reported.

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

In this study, a patient with lichen planopillaris experienced complete resolution of itching and hair shedding following treatment with a new platelet-rich plasma regimen, marking the first reported success in this context.

This article reviews the potential uses of PDRN in regenerative and aesthetic medicine, noting promising results in various treatments but highlighting the need for further long-term studies to confirm their safety and effectiveness.